Company intelligence / Profile preview

ViroChem Pharma

Montreal, Quebec, Canadainvestors.vrtx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ViroChem Pharma was a Montreal-based biotech company specializing in the discovery and development of antiviral therapeutics. At the time of its acquisition by Vertex Pharmaceuticals for approximately $375 million in March 2009, it had two promising hepatitis C virus polymerase inhibitors—VCH‑222 and VCH‑759—in early-stage clinical development. Both compounds demonstrated significant reductions in plasma HCV RNA as single agents and were well tolerated. The acquisition aimed to complement Vertex's existing HCV protease inhibitor telaprevir pipeline.

Therapeutic areas: Infectious Diseases
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

VCH-222

Phase 1

Indications: Hepatitis C

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on ViroChem Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroChem Pharma.

Explore the full profile